1. Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases. (December 2017) Authors: Loriot, Y.; Pagliaro, L.; Fléchon, A.; Mardiak, J.; Geoffrois, L.; Kerbrat, P.; Chevreau, C.; Delva, R.; Rolland, F.; Theodore, C.; Roubaud, G.; Gravis, G.; Eymard, J.C.; Malhaire, J.P.; Linassier, C.; Habibian, M.; Martin, A.L.; Journeau, F.; Reckova, M.; Logothetis, C. Journal: European journal of cancer Issue: Volume 87(2017) Page Start: 140 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 21LBA Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): Results from a pivotal multicenter phase II study (IMvigor 210). (September 2015) Authors: Rosenberg, J.; Petrylak, D.; Abidoye, O.; Van der Heijden, M.S.; Hofman-Censits, J.; Necchi, A.; O'Donnell, P.H.; Balmanoukian, A.; Loriot, Y.; Retz, M.; Perez-Gracia, J.L.; Dawson, N.A.; Balar, A.; Galsky, M.D.; Fleming, M.T.; Powles, T.; Cui, N.; Mariathasan, S.; Fine, G.D.; Dreicer, R. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S720 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 2537 Preliminary findings from PLATO: A two-period, phase 4, randomized, double-blind, placebo-controlled study of continued enzalutamide treatment beyond progression in men with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC). (September 2015) Authors: Attard, G.; Gurney, H.; Loriot, Y.; Borre, M.; Andresen, C.; Wu, K.; Taylor, C.; Amelsberg, A.; Taplin, M.E. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S487 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 2513 New prognostic factors for second-line targeted therapy (TT) in metastatic renal cell carcinoma (mRCC). (September 2015) Authors: Derosa, L.; Guida, A.; Albiges, L.; Massard, C.; Loriot, Y.; Galli, L.; Fizazi, K.; Escudier, B. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S478 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone. (18th October 2016) Authors: Massard, C.; Mateo, J.; Loriot, Y.; Pezaro, C.; Albiges, L.; Mehra, N.; Varga, A.; Bianchini, D.; Ryan, C. J.; Petrylak, D. P.; Attard, G.; Shen, L.; Fizazi, K.; de Bono, J. Journal: Annals of oncology Issue: Volume 28:Number 1(2017) Page Start: 90 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 2631 Inclusion of patients with urothelial bladder cancer in phase 1 trials: What is the impact?. (September 2015) Authors: Turpin, A.; Tergemina-Clain, G.; Kempf, E.; Postel-Vinay, S.; Massard, C.; Soria, J.C.; Loriot, Y. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S523 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 2637 Baseline circulating tumor cells (CTC) and serum heat shock protein 27 (Hsp27) levels are increased in advanced bladder cancer (BC) patients with poor prognostic factors: Results from the randomized phase 2 Borealis-1™ trial of first-line gemcitabine/cisplatin plus apatorsen or placebo. (September 2015) Authors: Petrylak, D.; Eigl, B.; Senkus, E.; Loriot, Y.; Twardowski, P.; Castellano, D.; Blais, N.; Sridhar, S.; Sternberg, C.; Retz, M.; Blumenstein, B.; Jacobs, C.; Stewart, P.; Bellmunt, J. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S525 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. 2626 Efficacy and safety of axitinib as third line therapy in metastatic renal cell carcinoma (mRCC): Retrospective analysis. (September 2015) Authors: Guida, A.; Matias, M.; Albiges, L.; Derosa, L.; Loriot, Y.; Massard, C.; Fizazi, K.; Escudier, B. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S521 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Detection of myeloid malignancies through cfDNA profiling in patients with advanced stage cancer. (October 2022) Authors: Tagliamento, M.; Aldea, M.; Verge, V.; Bayle, A.; Blanc-Durand, F.; Marinello, A.; Hadoux, J.; Loriot, Y.; Vasseur, D.; Nicotra, C.; Smolenschi, C.; Martin-Romano, P.; Hollebecque, A.; Ponce, S.; Lacroix, L.; Rouleau, E.; Marzac, C.; Italiano, A.; Besse, B.; Micol, J.B. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S11 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. High prevalence of Clonal Hematopoiesis of indeterminate potential (CHIP) associated mutations in elderly patients with solid tumors. (October 2022) Authors: Rodriguez, J.E.; Bayle, A.; Pages, A.; Danlos, F.X.; Goldschmidt, V.; Seknazi, L.; Vuagnat, P.; Martin Romano, P.; Hollebecque, A.; Smolenschi, C.; Mahjoubi, L.; Gazzah, A.; Bahleda, R.; Sarkozy, C.; Ouali, K.; Loriot, Y.; Marzac, C.; Ponce, S.; Italiano, A.; Micol, J.B. Journal: Journal of geriatric oncology Issue: Volume 13(2022)Supplement 1 Page Start: S10 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗